WWL229

Overview

WWL229 is a selective inhibitor of carboxylesterase 3 ( CES3 ) with an IC 50 1.94 μM. WWL229 attenuates LPS ( HY-D1056 )-induced pro-inflammatory cytokine mRNA levels, inhibits lipolysis and adipose thermogenesis, impairs mitochondrial function, and promotes lipid storage. WWL229 can be used for the research of obesity, insulin resistance, type 2 diabetes, and lung inflammation.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Obesity | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Carboxylesterase (CES) | Products > Signaling Pathways > PPAR | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Mitochondrial Metabolism

Product Information

• Catalog No.: HY-120602
• CAS No.: 1338575-28-2
• Molecular Formula: C16H22N2O5
• Molecular Weight: 322.36
• Purity: 99.49%
• Storage: Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (6.45 mM); Clear solution
• Availability: In-stock

Source

Original product source